{"id":"NCT03336645","sponsor":"Shire","briefTitle":"Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan","officialTitle":"A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in the Hospital or Emergency Room","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-10-23","primaryCompletion":"2019-08-19","completion":"2019-08-19","firstPosted":"2017-11-08","resultsPosted":"2020-07-31","lastUpdate":"2020-07-31"},"enrollment":25,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Nervous System Diseases"],"interventions":[{"type":"DRUG","name":"SHP615","otherNames":["Midazolam hydrochloride oromucosal solution","MHOS"]}],"arms":[{"label":"SHP615","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the efficacy, safety and pharmacokinetics of MHOS/SHP615 administered buccally in children with status epilepticus (convulsive) in a healthcare setting.","primaryOutcome":{"measure":"Percentage of Participants With Response Rate","timeFrame":"From start of study drug administration up to 30 minutes post-dose","effectByArm":[{"arm":"SHP615","deltaMin":80,"sd":null}],"pValues":[]},"eligibility":{"minAge":"3 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":17},"locations":{"siteCount":23,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":25},"commonTop":["Respiratory depression"]}}